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Abstract 
Drugs that suppress neuronal activity, including general anesthetics used 
in pediatric and obstetric medicine, trigger neuroapoptosis in the 
developing rodent brain.  Brief exposure of infant mice to sub-anesthetic 
doses of any of several individual anesthetic drugs (ketamine, 
midazolam, isoflurane) triggers a significant neuroapoptosis response.  
Propofol, a general anesthetic currently being used with increasing 
frequency in pediatric and obstetric anesthesia, is a very effective 
suppressant of neuronal activity.  Its mechanism of action is not fully 
understood; interaction with both GABAA receptors and NMDA 
glutamate receptors has been implicated.  Propofol has not been 
evaluated for apoptogenic potential, either alone or in combination with 
other anesthetic agents.  Therefore, we undertook the present study to 
determine whether propofol triggers neuroapoptosis in the infant mouse 
brain and, if so, what level of exposure is required to induce a significant 
neuroapoptosis response.  In a dose-finding pilot study we determined 
that infant mice become unresponsive (loss of righting reflex) to deep 
pain (tail prick) at an intraperitoneal (ip) dose of approximately 200 
mg/kg.  A dose-response evaluation was then undertaken which revealed 
that any dose above 50 mg/kg ip induces a statistically significant 
neuroapoptosis response in several regions of the developing mouse 
brain.  The magnitude of the response increased linearly in a dose 
dependent manner within the dose range tested (25 to 100 mg/kg ip). We 
conclude that a single sub-anesthetic (moderately sedating) dose of 
propofol triggers a significant neuroapoptosis response in the developing 
mouse brain.   
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1. INTRODUCTION 
The discovery of general anesthesia over 150 years ago transformed 
medicine and the practice of surgery. The ability to render a patient 
unconscious and insensitive to pain made surgery possible.  Thus, general 
anesthetics have become indispensable and are one of the most widely used 
class of drugs. 
Synaptogenesis, also known as ‘brain growth spurt’, involves cellular 
proliferation, differentiation and neuronal migration to target zones where 
formation of synapses result in the establishment of functional neuronal 
circuits (Price et al., 2006). Neurotransmitters (including GABA and 
glutamate) and their receptors exert fundamental roles in neuronal 
migration, dendrite filopodia stabilization, and synapse development and 
stabilization, although their role in the economy of neurodevelopment is not 
definitively known. 
All general anesthetics have either NMDA antagonist or GABA- 
mimetic properties (see the table below reprinted from Mellon RD). 
Table 1. Anesthetic agents and receptorial activity. (+ agonism; - antagonism) 
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Recent studies point towards the fact that pharmacological agents that 
dampen neuronal activity can be neurotoxic when administered during brain 
development. (Ikonomidou et al., 1999; Jevtovic-Todorovic et al., 2003; 
Young et al. 2005) 
Thus, NMDA receptor antagonists (MK801, ketamine, nitrous oxide), 
GABA mimetic drugs (phenobarbital, diazepam) (Bittigau et al., 2002; 
Jevtovic-Todorovic et al., 2003) and, ethanol and isoflurane, (Ikonomidou et 
al., 2000, Young et al., 2006; Jevtovic-Todorovic et al., 2003; Yon et al., 
2005), a mixed NMDA receptor antagonist/GABAA agonist, all trigger 
widespread apoptotic neurodegeneration when administered during early 
postnatal brain development to rodents (see the pictures below reprinted 
from Olney et al.). 
Figure 1. De Olmos cupric silver staining of postanatal day 7 rat thalamus after 8-12 hours from an 
anesthetic cocktail (midazolam, nitrous oxide and isoflurane in the first panel); different single used drugs 
(second panel). The intense staining of the different thalamic nuclei is an index of increased apoptic cell 
profiles. 
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Fig 2. Electronic microscopy. Early mitochondrial (edema, cristae disarrangement and membrane 
disruption) and late nuclear (chromatin lumps and blebbing) changes of ethanol induced apoptosis in 
neonatal age (postnatal 7 rat).  
 
In particular, ethanol has been the subject of substantial investigation and 
has been found to be responsible for the Fetal Alcohol Syndrome, where 
intrauterine exposure of the human fetus to ethanol causes a 
dysmorphogenic neuropathological syndrome including craniofacial 
malformations and a reduced brain mass.  The observed alterations in the 
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brain have been associated with a variety of neurobehavioral disturbances 
throughout the lifetime of the individual, ranging from 
hyperactivity/attention deficit disorder and learning disabilities in childhood 
to major depressive psychotic disorders in adulthood. 
A recent investigation demonstrated neuroapoptosis induced by a transient 
small increase in blood alcohol concentration in the infant mouse brain 
(Young and Olney, 2006), or by a single small dose of ketamine (Rubin, 
2005).  
Advances in pediatric and obstetric surgery have resulted in an increase in 
the complexity, duration, and number of anesthesia procedures, many of 
which are carried out in the womb (Sacrococcygeal teratoma, hydropic 
fetuses, Urinary decompression). 
“Image in the womb” 
 
 
In pediatric anesthesia, where “off label” use is often granted1, drugs (in 
both the NMDA antagonist and GABA-mimetic categories) are often 
administered in combination, which signifies that patients are being exposed 
                                                 
1
 National Institutes of Health. List of drugs for which pediatric studies are needed. Fed Regist 2006; 71: 
23931-6. 
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to the same or a very similar combination of mechanisms by which ethanol 
damages the human fetal brain. (Jevtovic-Todorovic et al., 2003).When 
animals that have been exposed to NMDA antagonists and/or GABA-
mimetics undergo behavioral testing in adulthood, they have been found to 
exhibit deficits in memory and learning , which is indicative of deficits in  
hippocampal and synaptic function .  
Common to the neurotoxic properties of all these substances is that the 
developmental vulnerability period in rodents (Bayer et al., 1993; Faustman 
et al., 2000) begins at birth and includes the first postnatal week of life 
(Ikonomidou et al., 1999, 2000).  
Thus, it coincides with the period of synaptogenesis and rapid brain growth 
(Dobbing and Sands, 1979, see picture below reprinted) 
 
The comparable period in humans spans from the third trimester of gestation 
to several years after birth (Dobbing and Sands, 1979; Huttenlocher, 1979). 
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Moreover new findings suggest that a second spurt in neurodevelopment 
may start during adolescence (Rice and Barone, 2000)  
Consequently, depending on the timing of administration, exposure to 
NMDA receptor antagonists, to GABAergic agonists or to a combination of 
both, may pose a risk of introducing iatrogenic diffuse brain damage which 
may likely not be recognized in early infancy, but manifest as a wide range 
of neuropsychiatric disorders in later life 
Regulatory agencies, including The Food and Drug Administration (FDA), 
are currently seeking to determine how these non-clinical data may be 
clinically relevant2. Although studies in primates are preferred, resources 
and funds limit the laboratory studies on these animals.  Thus, studies are 
commonly performed with other species, including rat and mouse (see table 
below reprinted from Mellon ED). 
 
Propofol (Glen JB, 1980), an intravenous anesthetic mostly affecting the 
GABAA receptor, is commonly used in adult (Rogers et al., 1980) but in 
pediatric (Purcell et al., 1987) anesthesia especially for induction and for 
                                                 
2
 Mellon RD, Simone AF, Rappaport BA. Use of anesthetic agents in neonates and young children. 
Anesth Analg. 2007 Mar;104(3):509-20. 
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sedation in radiologic or orthopedic procedures. It is requested an evaluation 
of its apoptogenic profile in dependant ages. 
In an attempt to find a neuroprotective strategy for rescuing developing 
neurons from drug-induced apoptosis, studies have identified lithium as a 
potential neuroprotective agent. One of the oldest and most effective 
psychiatric drugs for treatment of bipolar disorders, lithium is currently 
under extensive evaluation for its molecular biology activity and anti-
apoptotic gene modulation.  Specifically, lithium may demonstrate to reduce 
physiologically occurring neuronal cell death as well as cell stress induced 
apoptosis in different experimental models (ethanol, ketamine, trauma) 
To date, no in vivo o studies have been performed to assess the potential 
neuroapoptotic properties of propofol in neonate mice or to determine the 
minimal dose required to induce anesthesia and neuroapoptosis. 
Moreover, no studies have been performed to evaluate the potential 
neuroprotective properties of lithium against propofol-induced apoptosis.  
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a. GENERAL ANESTHESIA  
A definition of general anesthesia might simply be ‘a reversible, drug-
induced loss of consciousness’, recognizing that we will also need to specify 
a number of behavioural end points to characterize lack of responsiveness as 
the anesthetic concentration increases (Franks, 2006; Sonner, 2004). 
All currently used general anesthetic agents have “generally and 
rudimentally” either NMDA receptor-blocking or GABAA receptor-
enhancing properties (see picture below reprinted fron Ben-Ari). The 
pharmacological effects of these drugs are based on their ability to reduce 
neuronal excitability by either blocking N-methyl- D-aspartate (NMDA) 
receptor neurotransmission or enhancing γ-amino-butyric acid subtype A 
(GABAA) receptor function (Belelli et al., 1999; Miller, 2002; Dilger, 2002; 
Kress, 1995; Mihic et al., 1997). 
 
However, other receptors (two pore domain potassium channels, ATP 
dependent potassium channels, voltage gated ion channels for Na+, K+, 
Ca++), ions (magnesium, zinc) and neurotransmitters (acetylcholine, 
glycine, dopamine, serotonin, orexin, histamine) which activate an ion 
current or a second messenger pathway in the excitable cell (IP3, PIP2, 
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nitric oxide, tyrosin kinase, phospho-kinases/lipases, cAMP) are involved in 
the mechanisms of anesthesia. 
The principal mechanism underlying anesthetic compounds is the 
hyperdepolarization of target cells, resulting in the reduction of 
neurotransmission, formation and propagation of the signal and long term 
potentiation. In terms of functions, these biochemical alterations result in 
loss of consciousness, memory, movement and pain. 
On the molecular point of view, recent studies have shown a fervid 
modulation in gene products translation and post translation modifications. 
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3b. THE DEVELOPING BRAIN AND ITS SUSCEPTIBILITY  
Brain development is a well controlled process maintained through species 
and characterized by a mitotic phase, when cells replicates, and a post-
mitotic phase when cells migrate, maturate and establish connections 
depending on their genotype and phenotype (see pictures below reprinted 
from Buss RR  and Ben Ari Y). 
 
 
For the most part, these events occur during the embryonic stage of 
development; however, the higher the species, the longer the time required 
to accomplish maturation and allocation. 
Moreover the process of intercellular connectivity, also known as 
synaptogenesis, take most part during post natal life especially in primate 
                                                 
3
 Pollard TD and Earnshaw WC. Cell Biology. 2002, Saunders ed 
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and humans, and it is different for each brain region. The Granule Layer of 
the Cerebellum for instance (see picture below reproduced) has a 
complicated development, requiring several days/weeks to fully organize its 
structure, involving several receptors and second/messengers/enzymes, and 
under  a tight  hormonal control. 
 
Synaptogenesis is a highly regulated period of brain development that is 
exquisitely sensitive to environmental influences. The processes involved in 
neurodevelopment are conserved amongst species; in rodents, 
synaptogenesis occurs predominantly as a post-natal event, extending from 
approximately 2 days before birth to 2 weeks after birth, whereas in humans 
it begins during the third trimester of pregnancy and lasts until a few years 
after birth (Dobbing and Sands, 1979; Huttenlocher, 1979).  
Cellular mitotic check points remain activated during the initiation of 
synaptogenesis and in some brain area will retain this potentiality for all the 
organism life.  
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A developmental process known as programmed cell death (PCD) or 
naturally occurring cell death (NOCD) functions as a house-keeping 
mechanism for controlling the size of the peripheral or central nervous 
system cell population.  Early in development, cells are produced in excess 
and then compete for contacts with their cellular partners.  Cells that do not 
form sufficient synapses with their targets as well as unnecessary, redundant 
neurons and synapses are removed through the process of programmed cell 
death.  The term programmed cell death is meant to refer to the 
reproducible, stereotyped occurrence of cell loss and is not intended to 
imply that the cell death is predetermined, inherited from progenitors or 
inevitable.  Programmed cell death is widespread throughout the brain: up to 
70% of neurons are thought to be lost during development (Buss et al, 
2006). 
The number of brain cells we are born with remain stable after the growth 
spurt, unless pathological events occur. Reactivation of the machinery 
responsible for cell death may also be important in the etiology of 
neurodegenerative and neuropsychiatric disorders in the mature or aging 
nervous system. 
Neuronal survival is often dependent on physiological levels of electrical 
activity – blocking electrical activity in vivo or in vitro causes cell death 
(Gould et al, 1994; Mennerick and Zorumski, 2000; Hardingham and 
Bading, 2003). But what aspect of this activity is neuroprotective?  
• TARGET-AFFERENTS-GLIA the key elements for “neuron well 
being”.  
• Trophic Factors (Hormones, Growth Factors Depolarization Potential 
And Neurotransmitters). 
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The Classical View of Regulation of Developmental Neuronal Survival  
The peptide Neuronal Growth Factor (NGF), is derived from target tissues 
of dependent neurons and supports survival of sympathetic and many 
sensory neurons (Aloe, 2004). Target-derived neurotrophic factors act 
through receptor tyrosine kinases and downstream intracellular cascades in 
the presynaptic cell to support survival. The growth factors are generally 
believed to be present in limiting quantities, causing death of neurons that 
are at a competitive disadvantage for obtaining or utilizing the factor. 
CNS phenotypes in NGF knockout animals are not as severe as the 
peripheral nervous system (PNS) phenotypes, which show nearly absolute 
dependence on neurotrophic factors. There are several possible explanations 
for the apparent difference between PNS and CNS. One possibility is that 
other factors, including neuronal activity, serve as redundant survival-
promoting influences in the CNS, although some recent evidence suggests 
that activity is actually a prerequisite for CNS neurotrophic-factor 
signaling.Even in the PNS, however, activity levels are likely to participate 
in neuronal survival through alternate or synergistic mechanisms. 
Afferent-Dependent and Activity-Dependent Survival In Vivo 
Tetrodotoxin (TTX), a sodium channel blocker, and the microtubule and 
axonal transport disruptor colchincine kills post-synaptic tectal neurons in 
the developing chick. 
In the chick auditory system, transection or electrical block of the auditory 
nerve causes loss of nucleus magnocellularis neurons. 
Glutamate promotes survival in this system by activating a metabotropic 
glutamate receptor, which diminishes potentially apoptosis-inducing rises in 
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intracellular Ca2+ ([Ca2+i]) that result from high spontaneous firing levels 
in magnocellularis neurons. 
Evidence suggests that at least some neurons may depend on activity not 
only during development but throughout maturity. In the adult rat, ablation 
of the olfactory bulb results in anterograde apoptosis of a subset of 
superficial post-synaptic pyramidal neurons in the piriform cortex. 
The results are consistent with the idea that over-inhibition is directly toxic 
to many CNS neurons during development and perhaps into maturity. 
Synaptic communication can lead to exposure to neurotrophins. Synaptic 
signals (from glutamatergic neurons) can also cause Ca++ influx via NMDA 
receptors, and there is evidence that this influx accounts for a considerable 
part of the neuroprotective effects of electrical activity (Mattson and Duan, 
1999). 
In vivo blockade of NMDA receptors in the perinatal rat causes extensive 
apoptosis in many brain regions. Vulnerability to in vivo blockade of 
NMDA receptor activity in the rat dentate gyrus has been demonstrated in 
the first postnatal week. Increased apoptosis is also observed in the 
developing cerebellum following in vivo NMDA receptor blockade (Monti 
and Contestabile, 2000).  
Where NMDA receptor blockade (see the picture below the Yin and Yang 
of glutamate reprinted from Hardingham) does not kill the neurons, it can 
render them vulnerable to trauma (Bittigau et al., 1999).  
Progressive neuronal death in the adult striatum caused by chronic 
metabolic inhibition (by a succinate dehydrogenase inhibitor), and 
progressive neurodegeneration in the hippocampus triggered by mechanical 
trauma are also exacerbated by NMDA receptor blocakde. Studies on 
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cultured neurons also point to a neuroprotective role for synaptic NMDA 
receptor activity. 
 
Blockade of NMDA receptors in vivo negatively affects the subsequent in 
vitro survival of cerebellar granule cells.  
In cell cultures derived from the developing spinal cord, neuronal death 
caused by blockade of electrical activity can be attributed to the resulting 
lack of synaptic NMDA receptor activity, as can the effect of activity 
blockade in exacerbating staurosporine-induced apoptosis in cultured 
hippocampal neurons. 
These results, if applicable to the human brain, have clinical implications in 
cases of exposure to NMDA receptor antagonists, be they recreational drugs 
(e.g. phencyclidine, ketamine and ethanol), anaesthetics (e.g. nitrous oxide) 
or therapeutic drugs for intervention in NMDAreceptor-dependent 
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pathological conditions. Physiological NMDA receptor activity can also be 
reduced indirectly by sedatives, such as GABA mimetics.  
Work on the developing brain points to particular vulnerability to NMDA 
receptor blockade at this stage via, for example, exposure in utero to 
recreational drugs (including alcohol) or postnatally to NMDA-receptor-
antagonistic anesthetics. 
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Timing of receptor function availability and effect and subunit 
constitution  
A secondary aspect of the afferent-activation survival concept is the 
neurotransmitter receptor maturation and co-receptor variability (see 
pictures below reprinted from Ben Ari) The first aspect concerns mostly the 
NMDA sub unit receptor variance during the neurodevelopment and the late 
appearance of functional AMPA receptor, while the second aspect is related 
to the activity of GABAA receptor as excitatory receptor.  
At early stages of development, including the embryonic period and first 
week of postnatal life, GABA plays the role of main neurotransmitter of 
excitation (Obrietan et al, 2002).  
 
The paradoxical excitatory effect of GABA is caused by an inverted 
chloride gradient (related to the non activity of ionic contro-transporter and 
to a difference in resting potential and ionic receptor sensitivity) and, 
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therefore, a depolarizing direction of GABA type A (GABAA) receptor 
mediated responses.  
A recent study highlighted the involvement of hormonal control by oxytocin 
in current reversal and activity of GABAA receptor before delivery (Tyzio 
et al., 2006). This may prove to be a protective mechanism during the 
second stage or hypoxic phase of  the labour.  
Hypoxia has, however, been demonstrated to result in a necrotic form of 
neuron death with featured that are consistently different from those 
exhibited by neurons undergoing an apoptotic form of cell death 
(Northington et al., 2001; Ishimaru et al., 1999; Young et al., 2004) 
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Another type of GABAergic inhibition mediated by postsynaptic GABA 
type B (GABAB) receptors is not functional at early stage of life. In the 
neonatal rat hippocampus, GABA, acting via GABAA receptors, activates 
voltage-gated sodium and calcium channels and potentiates the activity of 
N-methyl-D-aspartate (NMDA) receptors by reducing their voltage-
dependent Mg2+ block (Ben-Ari et al., 1997). 
GABA facilitates BDNF expression, and BDNF facilitates the synaptic 
release of GABA. Signaling via the MAPK cascade and the transcription 
factor CREB (cAMP-response-element- binding-protein) appear to play a 
substantial role in this process. 
However, these physiologic mechanisms seem to be disrupted in pathologic 
conditions such asas epilepsy that occur more frequently in infants and 
children.Although most seizures in children are benign and result in no 
 26 
long-term consequences, increasing experimental animal data strongly 
suggest that frequent or prolonged seizures in the developing brain result in 
long-lasting sequelae.  
Such seizures may intervene with developmental programs and lead to 
inadequate construction of cortical networks rather than induction of 
neuronal cell loss. As a consequence, the deleterious actions of seizures are 
strongly age dependent: seizures have different effects on immature or 
migrating neurons endowed with few synapses and more developed neurons 
that express hundreds of functional synapses.  
This differential effect is even more important in human beings and 
subhuman primates who have an extended brain development period. 
Seizures during maturation result in a replay of development programs, 
which suggests that epileptogenesis or ictogenesis recapitulates ontogenesis. 
Therefore, to understand seizures and their consequences in the developing 
brain, it is essential to determine how neuronal activity modulates the main 
steps of cortical formation. 
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Molecular Biology of Neuronal Cell Survival and translation of cell 
depolarization in active pro-survival gene products 
Synaptic NMDA receptor activation in vivo results in the transcription of 
several immediate early genes controlled by, among others, the transcription 
factor cAMP-response-element- binding-protein (CREB). CREB is a 
member of a large family of structurally related transcription factors, 
including activating transcription factor 1 (ATF1), ATF2 (also know as 
CREBP1), ATF3 and ATF4, which bind to cAMP-response-element (CRE) 
promoter sites on target genes (Hardingham GE et al., 2002). 
Similarly, analysis of glutamate-mediated synaptic transmission in vitro 
showed that synaptic NMDA-receptor-dependent intra-cellular Ca2+ 
transients are potent activators of CREB and the CREB-regulated pro-
survival gene that encodes brain-derived neurotrophic factor (BDNF) (as 
well being highly neuroprotective).  
The transcription factor NFkB is also activated in neurons in vivo by 
synaptic stimulation (although NMDA receptor dependency was not tested) 
and in vitro by application of exogenous NMDA. 
Certain neurotrophins exert their neuroprotective powers through the 
activation of CREB. For example, nerve growth factor (NGF)-induced 
survival of sympathetic neurons is achieved via CREB-dependent activation 
of the anti-apoptotic gene Bcl-2. 
BDNF-induced survival of cerebellar granule cells occurs in part via CREB-
dependent transcriptional mechanisms.  
Interestingly, the expression of BDNF is itself regulated by CREB. 
Thus the activation of CREB has the potential to trigger a cycle of self-
reinforcing pro-survival events. Note that the strong CREB activation and 
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neuroprotection afforded by synaptic NMDA receptor activity have yet to 
be causally linked. 
CREB is activated by stressful stimuli such as hypoxia or UV-irradiation as 
well as by pro-survival stimuli, perhaps as an in-built defence mechanism. 
Activation of CREB in response to transient ischaemic episodes is proposed 
to contribute to establishing ischaemic tolerance or preconditioning and 
could well be mediated by NMDA receptor activation. Interestingly, 
resistance to hypoxic or ischemic death in different neuronal populations 
correlates positively with an ability to sustain active (phosphorylated) 
CREB. 
In neurons destined to die, CREB is only transiently phosphorylated. 
Mice lacking CREB (and that also lack the cAMP-response-element 
modulator CREM, another CREB family member) in the CNS during 
development show extensive neuronal apoptosis. Postnatal disruption of the 
CREB gene leads to progressive neurodegeneration in the hippocampus and 
dorsolateral striatum. 
Extracellular signal-regulated kinases are members of the mitogen-activated 
protein kinase (MAPK) family in neurons (Impey et al, 1998). Extracellular 
stimuli, such as nerve growth factor, ion channels associated with the N-
methyld-aspartate (NMDA)-type glutamate receptors, muscarinic 
acetylcholine receptors and nitric oxide, can trigger phosphorylation of 
ERK.  
The phosphorylation of ERK-1 and ERK-2 is mediated via the conserved 
small G protein Ras/MAPK kinase (Raf)/MAPK kinase (MEK) pathway, 
which plays a critical role in cell growth and differentiation. 
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MAPK pathway is important in brain functions, such as long-term memory 
formation, and additional evidence suggests that CREB is a nuclear target of 
MAPK during synaptic plasticity and memory consolidation (Blum et al., 
1998; Sgambato et al., 1998). 
A key element regulating ultimately the CREB activation but playing a 
major role in the control of early nuclear transcription pro-survival factors is 
phosphoinositide 3-kinase (PI3K). 
The transfer of signals from the plasma membrane to the cell nucleus is an 
exceedingly complex multistep process which strongly depends, among 
other components, on phosphatidyl inositol (PI) lipid signaling molecules. 
The bulk of inositol lipids reside in cell membranes where they are 
substrates for kinases, phosphatases, and phospholipases.  
 
The phosphatidylinositol 3-kinases (PI3K) have emerged as an important 
constituent of multiple signaling pathways being involved in the control of 
many critical cell responses (Cantley, 2002). 
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The PI3K family of enzymes is recruited upon growth factor receptor 
activation and produces 3' phosphoinositide lipids. The lipid products of 
PI3K act as second messengers by binding to and activating diverse cellular 
target proteins. These events constitute the start of a complex signaling 
cascade, which ultimately results in the mediation of cellular activities such 
as proliferation, differentiation, chemotaxis, vescicular trafficking, and 
glucose homeostasis, accumulating evidence proves their participation in 
type 2 diabetes mellitus and cell survival pathways (Vanhaesebroeck et al., 
2001; Downward, 2004).  
PI3K generates inositol phospholipids, which bind to a subset of PH 
domain-containing molecules thus recruiting them to the membrane. PDK1 
and PKB both contain PH domains and are downstream of PI3K. PDK1 
binds only to PIP3, whereas PKB can bind to both PtdIns(3,4)P2 and PIP3. 
Although both PIP3 and PtdIns(3,4)P2 can act as second messengers, the 
pathways mediated by PtdIns(3,4)P2 are not as well characterized as those 
of PIP3.  
Binding to second messenger lipids allows PDK1 and PKB (Akt) to interact 
with each other, resulting in the phosphorylation and consequent activation 
of PKB. Once activated, PKB can recruit many downstream effector 
molecules, which leads to diverse cellular responses. 
Several biological effects of PI3K are mediated through the activation of the 
downstream target Akt (PKB), a serine/threonine protein kinase, which 
belongs to the family of the AGC protein kinases (Martelli et al., 2006). 
A plethora of Akt substrates have been identified and these include, among 
the others, BAD, CREB, members of the FOXO family of transcriptions 
factors, Iκ-B kinase, procaspase-9, GSK-3-α/β, mTOR/FRAP, p21WAF1. 
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In conclusion (see picture below for major pathway involved in 
survival/apoptosis commitment reprinted from Benn and Woolf, Nature 
Reviews 2004, 5: 686-700): 
- Akt phosphorylates and inactivates the members of the FOXO 
transcription factor family which controls expression of certain pro-death 
genes;  
- Akt phosphorylates (and inactivates) the pro-death factor BAD; 
- Akt phosphorylates (and inactivates) GSK3-beta, which promotes BAX 
translocation to mitochondria. 
 
Flowchart of the supported mechanisms involving intrinsic and extrinsic apoptosis. Extrinsic and 
intrinsic apoptotic signalling pathways in neurons. Black lines represent apoptotic pathways, blue lines 
represent survival pathways. The extrinsic death pathway is initiated by binding of the extracellular 
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ligands, TNFα (tumour necrosis factor-α) or FAS (apoptosis antigen-1) ligand (FASL), to death receptors 
TNFR1 (TNF-receptor1) and FAS. TNFR1 activation leads to the formation of a TRADD–RIP–TRAF2 
(TNF-receptor death domain–receptor interacting protein–TNF-associated factor 2) complex, 
which signals through the NF-κB (nuclear factor-κB) survival pathway (blue lines) or the JNK (c-Jun-N-
teminal kinase)-death pathway (black lines). RIP activates procaspase 2 and cleaves BID (BH3 (BCL2 (B-
cell leukaemia/lymphoma-2) homology domain 3)- interacting agonist). The TRADD–FADD–FLICE 
(TNF-receptor death domain–FAS-associated death domain–FADD-like interleukin-1β) complex activates 
procaspase 8, triggering apoptosis through caspase 3 or cleavage of BID to tBID (truncated BID). FAS-
mediated death occurs through a FADD-mediated activation of procaspase 8 or DAXX (death-associated 
protein )-mediated activation of JNK. JNK modifies BID to jBID, allowing its translocation to the 
mitochondrion and release of SMAC/DIABLO (second-mitochondrialderived activator of caspases). The 
intrinsic apoptotic pathway is initiated at the mitochondrion by diverse stimuli. a | Membrane 
permeabilization is mediated by BH3-only proteins, which sequester and inhibit the supression of BAX (B-
cell lymphoma 2-associated protein X) by BCL2, allowing mitochondrial BAX translocation and the 
release of cytochrome c (Cyto c), SMAC/DIABLO, AIF (apoptosis-inducing factor) and HTRA2/OMI 
(high temperature requirement serine protease 2). b | Cytochrome c interacts with APAF1 (apoptosis 
protease activating factor-1) to recruit and activate caspase 9, forming the apoptosome, which activates the 
downstream executioner caspases 3 and 7. SMAC/DIABLO sequesters and inhibits IAP (inhibitor of 
apoptosis) proteins. AIF causes DNA degradation through PARP1 (poly(ADP-ribose) polymerase-1). ER 
(endoplasmic reticulum)-stress mediated apoptosis occurs through caspase-12 and caspase-3 activation. 
AIP1, ASK1-interacting protein 1; AKT/PKB, protein kinase B; AP1, activator protein-1; ASK1, 
apoptosis-signal-regulating kinase-1; BAD, BCL2-associated death protein; BAK, BCL2 agonist killer 1; 
BIM, BCL2-interacting mediator of celldeath; BMF, BCL2 modifying factor; BOK, BCL2-related ovarian 
killer protein; HRK, 5/harakiri; IκB, inhibitory subunit of NF-κB; IKK, IκB kinase; NIK, NF-κB-inducing 
kinase; NOXA, phorbol-12-myristate-13-acetate-induced protein (PMAIP1); PDK1/2, 3-phospho-inoside 
dependent kinase 1/2; PI3K, phosphatidyl inositol-3-kinase; pJNK, c-Jun amino (N) terminal kinase; p53, 
tumour suppressor gene; PUMA, P53-upregulated modulator of apoptosis; RAIDD, RIP-associated ICH-1 
homologous protein with a death domain; UV, ultraviolet light; XIAP, X-chromosome linked inhibitor of 
apoptosis protein. 
 
GSK3 originally identified as the protein kinase that phosphorylates and 
inactivates glycogen synthase, is a multifunctional serine/threonine protein 
kinase. There are two GSK-3 isoforms encoded by distinct genes: GSK-3a 
(51 kDa) and GSK-3b (47 kDa), and GSK-3 is a key participant in 
numerous signaling cascades, including the phosphatidylinositol 3-kinase 
(PI3-K) and Wingless (Wnt) pathways (Frame and Cohen, 2001). GSK-3 is 
also involved in a wide range of cellular processes, such as embryonic 
patterning, cell proliferation and axonal remodeling. 
GSK-3, and particularly the GSK-3b isoform, has recently been identified as 
an important key regulator of neuronal cell fate, having a proapoptotic effect 
in many settings (Jing et al., 2005).  
 33 
Insulin and several other neurotrophic factors induce inhibitory 
phosphorylation of GSK-3, mediated by the survival-promoting kinase Akt, 
and thereby promote neuronal survival. Consistent with this, when neurons 
are deprived of trophic stimulation, GSK-3 becomes activated and apoptotic 
cell death is initiated. 
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c. THE CONCEPT OF NEURONAL CELL DEATH PATTERN IN 
NEURODEVELOPMENT: APOPTOSIS AND MOLECULAR 
MECHANISMS 
Mechanisms of cell death have attracted a great deal of attention in recent 
years and much of this attention has been focused on apoptotic cell death.  
A large body of literature has examined various aspects of apoptotic cell 
death using a wide variety of techniques and model systems, including in 
vivo and in vitro, immunohistochemistry (TUNEL, Caspase 3), fine 
histology, electronic microscopy, cell flowcytometry, and proteomics (etc.). 
In general and for convenience sake the nomenclature for cell death 
included, Apoptosis, Oncosis, Necrosis, Autophagy and Programmed Cell 
Death or Naturally Occuring Cell Death (PCD or NOCD). 
In the neuroscience literature, it has increasingly been suggested that 
apoptotic mechanisms may underlie a wide variety of human brain disease 
processes.  
However, evidence supporting this assumption is less than compelling, a 
fundamental problem being that much of the research pertaining to CNS 
apoptosis has been conducted in cell cultures and, therefore, is of uncertain 
relevance to in vivo adult disease processes (Ishimaru et al., 1999; Dikranian 
et al., 2001).  
It has been reported that degenerating neurons in histological sections from 
autopsy brains of patients with Alzheimer’s disease and Huntington’s 
disease stain positive for the TUNEL (terminal deoxynucleotidyl 
transferase-mediated dUTP-biotin nick end labeling) reaction, a 
cytochemical assay putatively useful for diagnosing apoptotic 
neurodegeneration. However, it is now recognized that the TUNEL can 
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stain and label cells that are degenerating by either an apoptotic or 
nonapoptotic mechanism.  
Kerr4, who originally introduced the term “apoptosis,” defined the 
phenomenon in terms of its ultrastructural appearance. He proposed that all 
cell death processes could be classified as either “apoptotic” or “necrotic.” 
However, the focus of their studies was on liver, spleen, and other non 
neural tissues, so it is not clear to what extent their descriptive criteria for 
identifying apoptosis and necrosis are applicable to CNS neurons. These 
authors did cite a single example of neuronal apoptosis, namely 
physiological cell death (PCD), a suicidal process by which redundant or 
unsuccessful neurons are deleted from the developing brain.  
In an attempt to clarify this issue, Ishimaru et al. (see picture below showing 
cells at different stages of apoptosis and control as reference) undertook 
studies pertaining to cell death processes in the in vivo developing rat brain. 
They conducted a side by side comparison of a prototypic example of 
neuronal apoptosis with a prototypic example of excitotoxic 
neurodegeneration, using PCD as our example of apoptotic cell death. 
 
 
 
 
 
 
 
 
                                                 
4
 Kerr JFR, Wyllie AH, Currie AR. Apoptosis basic biological phenomenon with wide ranging 
implications in tissue kinetics. Br J Cancer 1972; 26: 239-57 
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Fig. 3. Electronic microscopy panels showing different stages of PCD in naturally occurring cell death or 
“apoptosis” in neonatal neurons from P7 rats. Panel 1 shows “control”, and panel 2 to 4 shows early to late 
changes of the cells. 
 
 
The conclusion was that DNA fragmentation tests are not specific for 
apoptosis and do not reliably distinguish apoptosis from excitotoxic cell 
death. 
It has been determined that concussive head trauma in the infant rat results 
in both an excitotoxic and an apoptotic cell death process.  These two cell 
death processes can be distinguished from one another quite readily by 
several criteria. Excitotoxic cell death (ECD) process occured only at the 
local site of concussive impact and transpired rapidly to end-stage cell death 
in a 4-h period, whereas the PCD (apoptotic) process occured at 
disseminated sites and evolved more slowly over a 16- to 24-h period. 
Finally, the two processes could be distinguished by their response to 
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treatment in that NMDA antagonist drugs that block NMDA glutamate 
receptors protected against the ECD process and, instead of protecting, 
caused a worsening of the apoptotic cell death process (Pohl et al., 1999). 
 
Fig. 4 Light- and electron-micrographs depicting features of rapid excitotoxic and delayed apoptotic 
neurodegeneration following trauma to the 7 day old rat brain. (A) Light micrograph depicting traumatic 
lesion in the parietal cortex 4 h after the mechanical impact. (B) Electron micrograph from the traumatized 
cortex of a rat pup 4 h after trauma showing an acutely degenerating neuron. The cytoplasm is massively 
swollen as are intracellular organelles, the endoplasmic reticulum and mitochondria. The nucleus 
demonstrates clumps of nuclear chromatin. (C) Silver-positive (DeOlmos cupric silver staining) cells in 
ipsilateral thalamic nuclei in the brains of 8 day old rats subjected to head trauma on day 7. (D) Electron 
microscopic evaluation of the cingulate cortex 16 h after parietal trauma reveals that the type and sequence 
of morphological changes meet the classical criteria for apoptosis. The neuron in (D) shows very early 
signs of apoptotic cell death which consist of the formation of electron dense spherical chromatin masses 
in the nucleus and a discontinuity in the nuclear membrane. In this early stage cytoplasmic organelles 
appear essentially normal.  
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The Role of Caspase-3 in the Apoptosis during neurodevelopment and 
the rationale for IHC of Caspase 3 as marker of “bona fide” apoptosis 
The initial definition of apoptosis was morphological: dying cells exhibit a 
characteristic pattern of changes, including cytoplasmic shrinkage, active 
membrane blebbing, chromatin condensation, and, typically, fragmentation 
into membrane-enclosed vesicles. This readily visible transformation is 
accompanied by a number of biochemical changes. Changes at the cell 
surface include the externalization of phosphatidylserine and other 
alterations that promote recognition by phagocytes. Intracellular changes 
include the degradation of the chromosomal DNA into high-molecular-
weight and oligonucleosomal fragments, as well as cleavage of a specific 
subset of cellular polypeptides. This cleavage is now known to be 
accomplished by a specialized family of cysteine-dependent aspartate-
directed proteases termed caspases. However a minor (relevant in other 
forms of PCD and excitotoxicity) role in the mechanism of apoptosis is 
related to the activity of Ca++-activated neutral cysteine protease called 
calpains and which are responsible for upstream mechanisms from caspase 
3 (Chan and Mattson, 1999). 
In mammalian cells, apoptosis is considered a gene-regulated phenomenon 
involving the coordinated action of several groups of protein molecules that 
trigger cell death and cause the cell to be degraded in an orderly sequence of 
steps (Meier 2000; Hengartner 2000). Two major apoptotic pathways have 
been described, one designated as ‘‘extrinsic’’ and the other ‘‘intrinsic’’ 
(Yon et al., 2005). Caspases, a family of cysteine-containing, aspartate-
specific proteases, characteristically are key players in both pathways. In the 
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extrinsic pathway, the cell death signal activates caspase-8, which can 
directly or indirectly activate effector caspases, including caspase-3.  
 
 
In the intrinsic pathway, proapoptotic members of the Bcl-2 family, such as 
Bax, translocate to mitochondrial membranes, causing increased membrane 
permeability and leakage of cytochrome c into the cytoplasm. Cytochrome c 
binds to APAF-1 and caspase-9, causing activation of caspase-9, which in 
turn cleaves and activates effector caspases, such as caspases-3, -6, and -7. 
Activated effector caspases target many structural and functional proteins 
and lead to the proteolytic degradative morphological changes that typify 
apoptosis. Mammalian developing brains express high levels of caspase-3 
zymogen, which is cleaved and activated under various circumstances 
involving neuronal apoptotic cell death. 
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Biochemical Pathways involved in neurodevelopmental apoptosis : 
Ethanol Paradigm 
It has been shown in several recent studies that transient exposure of infant 
rats (Ikonomidou et al., 2000) or mice (Olney et al., 2002) to ethanol during 
the developmental period of synaptogenesis triggers widespread apoptotic 
degeneration of neurons in many brain regions. 
The neurodegenerative reaction transpires rapidly over a period of hours to 
end-stage cell death, meets ultrastructural criteria for apoptosis (Dikranian 
et al., 2001), is Bax dependent (Young et al., 2003) and cannot be evoked in 
Bax knock-out mice, and involves ultrastructurally detectable dissolution of 
mitochondrial membranes (Dikranian et al., 2001), redistribution of 
cytochrome c, and a robust display of immunohistochemically detectable 
caspase-3 activation (Olney et al., 2002). Moreover a rapid suppression of 
ERK and Akt phosphorylation preceeds ethanol-induced caspase 3 
activation (Young et al., 2006). 
Caspases-6, -7, and -8 are not involved in this neuroapoptosis phenomenon 
(Olney et al., 2002; Young et al., 2003), which appears to preferentially use 
the intrinsic mitochondrial pathway and caspase-3 as the primary protease 
effector molecule. 
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Molecular Mechanisms leading to disseminated apoptosis in the 
developing rat brain: the NMDA receptor blockade paradigm  
Synaptic NMDA receptor-induced membrane depolarization plays a vital 
role in providing and sustaining neurotrophic support through activation of 
pro-survival protein kinase signaling pathways (Hardingham and Bading, 
2003; Lovinger et al., 1989; Farber and Olney, 2003; Hansen et al., 2004) 
triggered by calcium-dependent signaling transduction.  
In particular, there is compelling in vitro evidence for the trophic role of 
synaptic NMDA receptors via coupling to extracellular signal-regulated 
protein kinase (ERK1/2), calcium/calmodulin-dependent kinase IV 
(CaMKIV) and cAMP-responsive element binding protein (CREB).  
Since CREB regulates transcription of many pro-survival genes, including 
bdnf (Hardingham et al., 2003) and bcl2, the association of NMDA 
receptors to ERK1/2-CREB and CaMKIV-CREB signaling is suggested to 
be important for NMDA receptor-induced trophic effects during brain 
development. 
Constitutive activation of CREB promotes cell proliferation and over-
expression of dominant-negative CREB in various mammalian cell cultures, 
including neurons, reduces cell viability. CREB gene null mutations result 
in extensive neuronal apoptosis and perinatal death of homozygous mice, 
and conditional CREB knockout mice display progressing apoptotic neuron-
degeneration during postnatal forebrain development. 
MK801 exposure induced a transcriptional down-regulation of mRNAs 
encoding the synthesis of BDNF, GDNF, and to a lesser degree NT-3. The 
loss of neurotrophin mRNA was a rapidly progressing process and 
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depression of BDNF and GDNF gene expression persisted during neonatal 
NMDA receptor blockade. 
Particularly in BDNF signaling via Ras, a consequence of repetitive MK801 
administration was the reduction of ERK1/2 catalytic activity, down-
regulation of CREB phosphorylation and a transcriptional reduction of the 
anti-apoptotic protein Bcl2.  
These regulatory events occurred temporally in parallel to the drop in 
neurotrophin expression, signifying a causal relationship. Such causal 
relationship was further supported by the observation that P7 synRas mice 
(mutant transgenic mice with extra replicants of Ras), which were less 
susceptible to MK801-induced neuronal apoptosis, displayed higher levels 
of phosphorylated CREB and increased ERK1/2 phosphorylation post-
natally, indicating that Ras-induced neuroprotection was associated to a 
specifically enhanced signaling response of the ERK1/2-CREB pathway. 
Developmental blockade of NMDA receptor function in vivo induces 
disseminating apoptosis via uncoupling of NMDA receptor function 
specifically from ERK1/2-CREB signaling.  
The notion is further supported by the observation that upstream inhibition 
of neonatal ERK1/2 activity by intra-cerebroventricular administration of 
the mitogen-activated extracellular kinase (MEK) inhibitor induces neuronal 
death in the P7 rat brain. Furthermore, erythropoietin supplementation partly 
rescues newborn rats from MK801-induced brain damage by enhancing 
BDNF and GDNF production and restoring ERK1/2 signaling (Dzietko et 
al., 2004), signifying that he observed partial deactivation of the ERK1/2-
CREB signaling is usually linked to the pathogenesis of MK801-induced 
cell death and it is not simply an accompanying phenomenon. 
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Disseminating apoptotic neurodegeneration in 7 days rats following 
treatment with anticonvulsants (see image below reproduced by Ikonomidou 
C), such as γ-aminobutyric acid (GABA) mimetics (phenobarbital, 
valproate) and a voltage-gated sodium channel blocker (phenytoin), is 
preceded and sustained by a progressing down-regulation of cortical and 
thalamic BDNF and NT-3 mRNA levels as well as reduced ERK1/2 and 
Akt phosphorylation (Bittigau et al., 2002).  
Also, postnatal ethanol (a composite NMDA receptor antagonist/GABAA 
receptor agonist) exposure at minimal concentration (far away from 
intoxication levels), decreases cortical ERK levels (Young and Olney, 
2006), suggesting that down-regulation of neurotrophin-associated pro-
survival kinase activity is a common underlying effect of pharmacological 
agents that depress neuronal excitation in the developing brain. 
 
Ethanol-Induced Neuroapoptosis – C57BL/6 Mouse Brain
Ethanol
Saline
 
Dose–response and minimal effective dose considerations 
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Neuroapoptosis in the infant mouse brain can be triggered by a transient 
small increase in blood alcohol concentration (Young and Olney, 2006), or 
by a single low dose of ketamine (Rudin, 2005). 
Anesthetics responsible for neurotoxicicity in adult age but apoptosis 
during neurodevelopment 
A comparative evaluation of the neurotoxic properties of ketamine and 
nitrous oxide in the adult and infants (Jevtovic-Todorovic et al., 2003; 
Jevtovic-Todorovic et al., 2000; Farber and Olney, 2003). 
 
 45 
d. PROPOFOL 
Propofol is a 2,6-diisopropylphenol with sedative-hypnotic properties 
(Mazoit, 2006; Larjiani et al., 1989; Kanto and Gepts, 1989; Trapani et al. 
2000; Rigby-Jones et al., 2002). Because of its slight solubility in water, the 
drug is formulated as an emulsion for clinical use.  
Propofol is an oil at room temperature and insoluble in aqueous solution. 
Present formulations consist of 1% or 2% (w/v) propofol, 10% soybean oil, 
2.25% glycerol, and 1.2% egg phosphatide. Disodium edetate (EDTA) or 
metabisulfite is added to retard bacterial and fungal growth. 
It is highly lipophilic and distributes extensively in the body. The blood 
concentration-time profile of propofol after an iv bolus injection follows a 
three-compartment model with half-lives of 2-4 min, 30-45 min, and 3-63 h, 
respectively. Propofol is extensively metabolized by the liver prior to its 
elimination by the kidney. Following an iv dose of 2-2.5 mg/kg, loss of 
consciousness occurs in less than one minute and lasts for approximately 
five minutes.  
This highly lipophilic agent has a fast onset and short, predictable duration 
of action due to its rapid penetration of the blood-brain barrier and 
distribution to the CNS, followed by redistribution to inactive tissue depots 
such as muscle and fat. On the basis of pharmacokinetic-pharmacodynamic 
modelling, a mean blood-brain equilibration half-life of only 2.9 minutes 
has been calculated. In most studies, the blood concentration curve of 
propofol has been best fitted to a 3-compartment open model, although in 
some patients only 2 exponential phases can be defined. The first 
exponential phase half-life of 2 to 3 minutes mirrors the rapid onset of 
action, the second (34 to 56 minutes) that of the high metabolic clearance, 
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whereas the long third exponential phase half-life of 184 to 480 minutes 
describes the slow elimination of a small proportion of the drug remaining 
in poorly perfused tissues. Thus, after both a single intravenous injection 
and a continuous intravenous infusion, the blood concentrations rapidly 
decrease below those necessary to maintain sleep (around 1 mg/L), based on 
both the rapid distribution, redistribution and metabolism during the first 
and second exponential phases (more than 70% of the drug is eliminated 
during these 2 phases).  
During long term intravenous infusions cumulative drug concentrations and 
effects might be expected, but even then the recovery times do not appear to 
be much delayed. The liver is probably the main eliminating organ, and 
renal clearance appears to play little part in the total clearance of propofol. 
On the other hand, because the total body clearance may exceed liver blood 
flow, an extrahepatic metabolism or extrarenal elimination (e.g. via the 
lungs) has been suggested. Approximately 60% of a radiolabelled dose of 
propofol is excreted in the urine as 1- and 4-glucuronide and 4-sulphate 
conjugates of 2.6-diisopropyl 1,4-quinol, and the remainder consists of the 
propofol glucuronide. Thus for hepatic and renal diseases, co-medication, 
surgical procedure, gender and obesity do not appear to cause clinically 
significant changes in the pharmacokinetic profile of propofol, but the 
decrease in the clearance value in the elderly might produce higher 
concentrations during a long term infusion, with an increased drug effect. 
The action of propofol involves a positive modulation of the inhibitory 
function of the neurotransmitter gama-aminobutyric acid (GABA) through 
GABAA receptors. It directly activates GABA(A) receptors. Recent results 
from recombinant human GABAA receptor experiments and findings from 
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the work exploring the effects at other receptors (e.g., glycine, nicotinic, and 
M1 muscarinic receptors) have been assessed. 
In fact propofol inhibits the NMDA receptor and modulates calcium influx 
through slow calcium ion channels (Grasshoff and Gillessen, 2005).  
In vitro investigations have shown that propofol at clinical relevant 
concentrations (1-10 µM) inhibited NMDA receptor-dependent ERK 
phosphorylation and activation of GABAA receptors by propofol decreasing 
[Ca2+]i and promotes cell death in immature hippocampal neurons (Azoker 
et al., 2006; Wang et al., 2006; Kozinn et al., 2006). The ERK pathway 
transmits  glutamate receptor signals to Elk-1 and CREB for the facilitation 
of gene expression. The Elk-1– and CREB–facilitated gene expression is 
implicated in the development and maintenance of LTP and learning and 
memory (picture below reproduced by Kozinn). 
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Schematic illustration of propofol inhibition of long-term potentiation (LTP) through inhibiting N-methyl-D-aspartate receptor 
(NMDAR)–dependent activation of mitogen-activated protein kinases (MAPK)/extracellular signal–regulated protein kinases 1/2 
(ERK1/2). Sequential events underlying the NMDAR/ERK-dependent LTP are initiated with an increase in Ca2_ influx through 
activated NMDAR channels. Ca2_ signals then activate the Ras–ERK cascade, probably through phosphatidylinositol 3-kinase (PI3K) 
and Ca2_/calmodulin-dependent protein kinases (CaMKs). Active ERK1/2 proteins translocate into the nucleus to activate their 
transcription factor targets, cyclic adenosine monophosphate response element–binding protein (CREB) and Elk-1, leading to the 
facilitation of inducible gene expression implicated in the maintenance of long-lasting LTP. Propofol inhibits NMDARs and thus 
blocks the NMDARmediated activation of the ERK pathway and impairs the NMDAR/ERK-dependent LTP. The inhibitory effect of 
propofol may result from its inhibition of phosphorylation of NMDAR NR1 subunits at serine residues 897 and 896. CRE _ cyclic 
adenosine monophosphate response element; Glu _ L-glutamate; MEK _ MAPK kinase; SRE _ serum response element. 
 
Besides the adverse effects are generally referred to the classical range of 
“allergic “ anaphylactic reactions or to CNS-striatal reactions (myoclonic, 
athetotic like movements) and hemodynamic effects (brief tachycardia 
followed by bradycardic hypotension) at the induction of general anesthesia, 
a more complex metabolic syndrome is caused by prolonged infusion of 
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propofol, especially at higher concentrations, which are not labeled in the 
US. 
Propofol infusion syndrome (Kumar et al., 2005) is described in the 
pediatric literature as metabolic acidosis, rhabdomyolysis, and bradycardia 
that results in death. The pathogenesis of this syndrome is thought to be 
activation of the systemic inflammatory response, which culminates in 
acidosis and muscle necrosis. 
Propofol can impair the mitochondrial electron transport chain in isolated 
heart preparations in laboratory animals. Data show that propofol affects 
fatty-acid oxidation by inducing a rise in malonylcarnitine. This inhibits the 
transport protein for long-chain fatty acids (carnitine palmityl transferase 1). 
Medium-chain and short-chain fatty acids will continue to penetrate into the 
mitochondria by diffusion. However, a secondary inhibition of the 
respiratory chain at complex II also occurs, shown by the rise in C5-
acylcarnitine. The resultant lack of substrates and the build up of 
intermediaries in the metabolism of long-chain, medium-chain, and short-
chain fatty acids might account for the clinical features. 
So far, however, propofol has been granted as the easiest and most “safest” 
agent for pediatric general anesthesia induction and for procedural sedation, 
especially for anesthesiologists. Propofol as well is usually used in different 
combinations with other sedatives and anesthetics in order to achieve a 
reliable sedation (Akin et al. 2005; Tsui et al., 2005; Cravero and Blike 
2004). 
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e. LITHIUM 
Lithium is an element discovered over 175 years ago (1817), but it was not 
until the seminal work of the Australian physician/scientist, John Cade 50 
years ago, and subsequent clinical studies by Mogens Schou, that lithium 
was seen by modern psychiatry as an effective treatment for manic-
depressive illness (MDI, Bipolar Affective Disorder). 
Despite its role as one of psychiatry’s most important treatments, however, 
the biochemical basis for lithium’s therapeutic effects remains to be fully 
elucidated (Hallcher and Sherman, 1980; Jope 1999; Manji et al 1995). 
Considerable research has identified transmembrane cellular signaling 
pathways, in particular the protein kinase C signal transduction pathway as 
the relevant target for many of lithium’s effects (Jope 1999; Manji et al 
1995). 
However Lithium exerts major effects on the cytoprotective protein, bcl-2,  
(Chen and Chuang, 1999) as well as on GSK-3b (glycogen synthase kinase 
3b). Lithium’s effects on bcl-2 and GSK-3b are not responsible for all of 
lithium’s therapeutic effects, but rather that these biochemical effects may 
play a major role in long term neurotrophic/neuroprotective effects (Chuang 
DM, 2002 and 2005; Corbella and Vieta, 2003). 
Lithium at therapeutic doses increases the activities of two prominent 
transcription factors, AP-1 and CREB (cyclic AMP–response element 
binding protein), in cultured cerebellar granule cells and in distinct brain 
areas (e.g., frontal cortex, amygdala, hippocampus, and cerebellum). 
Lithium also exerts its effects on the cell survival factor, Akt, which is a 
downstream kinase of phosphatidylinositol 3-kinase (PI 3-kinase). Lithium 
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treatment in rats was found to rapidly activate PI 3-kinase, resulting in 
increased phosphorylation of Akt at Ser473 and enhanced Akt activity. 
The MEK/ ERK MAP kinases are upstream of CREB and known to be 
involved in cytoprotection. Treatment with glutamate induces a rapid 
increase in MEK activity and this is potentiated by long-term lithium 
pretreatment, an effect blocked by the MEK inhibitor, PD 98059. 
Long-term lithium exposure is necessary to maintain higher activated CREB 
levels in cerebellar granular cells subjected to glutamate excitotoxicity and 
that this may be the result of the inhibition of protein phosphatase 1 as well 
as promotion of the activities of MEK/ERK by itself. 
 
In the picture above some of the major molecular actions of lithium are 
described (reproduced from Corbella and Vieta, 2003). 
In particular (see picture that follows) c-Jun N-terminal kinase (JNK) and 
p38 kinase, another member of the MAP kinase family, are activated by 
site-specific phosphorylation in response to a variety of apoptotic insults. 
The p38 kinase and JNK often act synergistically to enhance AP-1 binding 
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activity. AP-1 binding activation is involved in glutamate excitotoxicity and 
is a target of lithium as part of lithium-induced neuroprotection. Glutamate, 
through NMDA receptor activation, causes a rapid activation of JNK and 
p38 kinase, which then phosphorylate c-Jun (at Ser63) and p53 (at Ser15), 
leading to a robust increase in AP-1 binding that precedes apoptotic death. 
lithium transiently increases intracellular BDNF followed by an increase in 
levels of phosphorylated TrkB (at Tyr490). Thus, long-term lithium 
enhances BDNF expression, secretion, and subsequent activation of TrkB 
receptors. 
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AIM OF THE PROJECT. THE HYPOTHESIS TEST 
Our goal was to define the minimal single anesthetic dose of propofol, a 
GABA agonist anesthetic with possibly NMDA antagonist actions, used for 
induction and maintenance of general anesthesia, and for maintenance of 
sedation in intensive care and others settings, able to induce neuroapoptosis 
and to correlate with histology marker of apoptotic cell death and to the 
molecular mechanisms involved in apoptosis and neuroprotection in neonate 
mice. We aimed as well to find the minimal dose of propofol able to induce 
a significant increase in neuroapoptosis compared to the physiologic 
occurring cell death (POCD). 
Lithium affects the basal rate of apoptosis as per activated caspase 3 POCD 
and it is able to decrease the drug induced apoptosis as well. We decided to 
test the effects of lithium on propofol induced neuro-apoptosis. 
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MATERIALS AND METHODS 
Animals and Procedures:  All animal procedures were conducted in 
accordance with guidelines developed by the National Academy of Science 
and were approved by the Washington University Animal Care Committee.  
Infant C57BL6 mice were used in all experiments.  Previously we have 
observed that at postnatal day 5 and 7 (P5 to P7) when C57BL/6 mice are at 
an average body weight of about 2.5 to 3.5 g they are maximally sensitive to 
drug-induced neuroapoptosis, but at P7 there is a rapid shift in sensitivity so 
that as they become only slightly older they become less sensitive to this 
neurotoxic effect.  Therefore, for the present study we used P5 mice and 
with a body weight ≤ 3.0 g.  Previously we have observed that there is 
considerable litter variability in the rate of apoptosis that occurs 
spontaneously in infant mice, and the spontaneous rate covaries with their 
sensitivity to drug-induced neuro-apoptosis (litters that have more 
spontaneous apoptosis are correspondingly more sensitive to drug-induced 
apoptosis).  Therefore, an equal number of pups was assigned from each 
litter to the experimental and control conditions.  In addition, although we 
have observed in prior studies that male and female pups are equally 
sensitive to drug-induced neuro-apoptosis, we assigned, as nearly as 
possible, an equal number of male and female animals to the control and 
experimental conditions. 
The study was undertaken in three phases.   
Drugs preparation: Propofol used in the experiments was a 1% of 2,6-
diisopropylphenol in a intralipid based emulsion preservatives free (Astra 
Zeneca). A basic concentration of 10 mcg/g (10 mcL/g) was used and 
volume adjusted as per final dose required. 
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Lithium Carbonate (Sigma, St Louis) was diluted in distilled water and 
solved by hydrogen chloride and buffered with sodium hydroxide at 
physiological pH for a final concentration of 6 mEq/kg (10 mcL/g). 
PHASE 1. Pilot study. Minimal anesthetic dose of propofol. Intralipid 
emulsion apoptogenesis. 
We tested the ability of propofol to induce and maintain anesthesia in 
neonate C57/B6 mice finding the Minimal Effective Dose of propofol. A 
dose of 300 mg/kg was chosen as starting dose as per previous reports 
(Irifune et al. 2003), and progressively reduced to 200, 150 and 100 mg/kg. 
Once assessed that the average induction time by an intra-peritoneal (IP) 
route was faster than through subcutaneous (SC), a combined IP and SC 
drug administration route were operated to maintain a faster but smoother 
induction and a better controlled release. 
Anesthesia state was defined as the occurrence of loss of the righting reflex 
(LRR) and absence of spontaneous movements sustained for more than 30 
seconds over a period of observation of 5 minutes. The concurrent 
immobility to tail pricking was not defined as necessary to define anesthesia 
in the animals. A sub-anesthetic state was defined by loss of the righting 
reflex for less than 30 seconds but accompanied by spontaneous movements 
over a 5 minutes observation time. The animal behavior was then assessed 
every 10 minutes in the first hour and every 30 minutes in the remaining 
experimental time (5 hours total after the injection). 
Respiration rate and quality of breathing was qualitatively assessed. 
Blood glucose was sampled randomly and equally between groups and 
checked with an Ascensia® Contour blood stick machine (Bayer), in order 
to evaluate possible hypoglycemic and metabolic interference of propofol. 
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The mice randomly chosen for glucose blood test were carefully stabbed 
over their pads to obtain a single large blood drop then collected on the 
glucose test strip. Only one collection was made to avoid exsanguination 
(about three hours after the exposure time). 
The vehicle used as control in the formal further studies has been the 
intralipid solution 10% diluted to 1% with normal saline, previously 
employed as control, matching the lipid emulsion of the propofol (Irifune et 
al., 2003). 
In a separate pilot experiment we tested then the vehicle intralipid 10% 
emulsion in terms of activated caspase 3 pattern compared to normal saline 
(data no shown), and it showed no differences.  
PHASE 2. Minimal apoptogenic dose. 
We exposed mice to decreasing concentrations of propofol based on the 
minimal anesthetic effective dose found in the pilot study. A geometric 
decrements from that dose was used in order to find the minimal 
apoptotic/effect dose. The different dosages were correlated to the apoptotic 
rate as per by activated caspase 3 profiles. As per phase 1 protocol, the 
administration of propofol was equally effective through the IP and SC 
route. However the IP route was preferred because faster at lower doses and 
closer to the induction qualities of a clinical setting. 
Pups from each litter, were distributed equally among the treatment 
conditions (vehicle/control intralipid, 25 mg/kg propofol IP, 50 mg/kg 
propofol IP, 100 mg/ kg IP propofol). 
PHASE 3. Lithium neuroprotection 
In previous experiments, lithium at 3 and 6 mEq/kg has shown to reduce 
POCD. 
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As well neonate mice exposed to different drugs with GABA mimetic and 
NMDA antagonism (ethanol, ketamine, isoflurane) but pretreated or 
concurrently injected with lithium showed no increase in the apoptotic cell 
profiles as per cleaved caspase 3.  
Because the minimal apoptotic dose of propofol significantly inducing 
caspase 3 activation was found to be 50 mg/kg, and because the most 
effective dose of lithium is 6 mEq/kg, these doses were used as reference.  
Pups were distributed equally among the treatment conditions 
(vehicle/control 10 mcL/g, lithium 6 Meq/kg IP, Propofol 50 mg/kg IP, 
Propofol 50 mg/ kg IP plus lithium 6 Meq/kg IP). After the drug/s injection 
the pups were allowed to rest in a heated pad (30 degrees C) for 5 hours. 
Regular observations were guaranteed. After the 5 hours the mice were 
humanely killed by pentobarbital overdose and perfused as per protocol 
described. 
Anesthesia exposure conditions:  The mice pups were removed from the 
dam and injected with the proper amount of drug as per protocol 
intraperitoneally, subcutaneously or both. The duration of exposure in all 
experiments was 5 hrs before the humane killing. 
Temperature was maintained constant during the observational time as per 
‘natural” conditions (28-32 degrees Celsius) in a cotton covered cage and 
with the use of an irradiating lamp, at room air and humidity.  
After 5 hrs (unless for western blotting) of anesthesia (or exposure to 
vehicle), the pups were removed from the cage and humanely killed.   
Histopathology: pups were deeply anesthetized with pentobarbital and 
perfused with fixative (4% paraformaldehyde in Tris buffer) through the left 
cardiac ventricle and ascending aorta.  The brains were removed from the 
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skull and immersed in the perfusion fixative overnight in the refrigerator, 
then the brains were bisected sagittally, embedded in Agar gel, sectioned 
serially by vibratome in the sagittal plane and stained 
immunohistochemically (IHC) for activated caspase-3 (AC3) by methods 
recently described 5. Briefly, vibratome sections (70 µm thick) were washed 
in 0.01M PBS, quenched for 10 min in a solution of methanol containing 
3% hydrogen peroxide, then incubated for 1 hr in blocking solution (2% 
BSA/0.2% milk/0.1 % Triton X-100 in PBS), followed by incubation 
overnight in rabbit anti-active caspase-3 antiserum (D175, Cell Signaling 
Technology, Beverly, Massachusetts) diluted 1:1000 in blocking solution. 
Following incubation with D175 primary antibody, the sections were 
incubated for 1 hr in secondary antibody (goat anti-rabbit 1:200 in blocking 
solution), and then reacted in the dark with ABC reagents (standard 
Vectastain ABC Elite Kit, Vector Labs, Burlingame, CA) for 1 hour. The 
sections were then washed 3 times with PBS, and incubated with VIP 
reagent (Vector VIP substrate kit for peroxidase, Vector Labs, Burlingame, 
CA) to develop a purple color. The slices were mounted either on PBS or 
distilled water. After overnight dehydration at room temperature the slides 
were alcohol dehydrated, clarified through a citric based solvent, then 
cover-slipped in DPX. 
Quantitative cell counts. For quantitative counts of apoptotic neurons, three 
sections were chosen in a systematically specified sampling manner. This 
permitted counting representatives sections for Cortex (orbital, frontal, 
                                                 
5
 Young, C, Jevtovic-Todorovic, V, Qin, YQ, et al. Potential of ketamine and midazolam, individually or in combination, to 
induce apoptotic neurodegeneration in the infant mouse brain.  Brit J Pharmacol 2005; 146:189-97 
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parietal, occipital, cingulate, retrosplenial, subiculum, piform, amygdale), 
and Caudate from half of each brain.  
Lateral coordinates6 were respectively 0.40-0.90 mm, 1.40-1.90 and 2.40-
2.90 for cortex and 1.40-1.90 mm, 2.40-2.90 and 3.40-3.90 for caudate from 
the medial commissure of the half cerebrum. 
These sections were imaged and quantitatively evaluated with the help of a 
stereology system consisting of the following components: Stereo 
Investigator (MicroBrightField, Inc, Colchester, VT) on a Pentium III PC, 
connected to a Prior Optiscan motorized stage (ES103 XYZ system, Prior 
Scientific Inc, Rockland, MA) mounted on a Nikon Labophot-2 microscope. 
The boundaries of the brain regions of interest (cerebral cortex and caudate-
putamen) were traced into the PC and from the tracings Stereo Investigator 
calculated the area in each section.   
In the cortex, the majority of AC3-positive profiles were in layer II, but 
counts were performed across the entire extent of the cerebral cortex.  In the 
caudate-putamen, AC3-positive profiles were present in scattered or loosely 
clustered distribution throughout both the dorsal and ventral portions.  
Caspase-3 positive neurons with dendrites or axons visible were all counted. 
For those profiles without obvious dendritic processes, only those with a 
size larger than 8 µm were counted. The population estimator function of 
Stereo Investigator was used to mark each profile while it was counted to 
ensure that no profile would be missed or counted twice.  
To obtain an estimate of the total density of AC3-positive profiles in the 
reference brain region (cerebral cortex or caudate/putamen), we summed the 
counts from three representative sections containing that brain region, 
                                                 
6
  Paxinos G and Watson C. The rat brain in stereotaxic coordinates. II ed. Academic Press 1986. 
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dividing for the total surface area of the three sections, multiplying for the 
section thickness (70 µm) and correcting the density per Number of Cell per 
mm
3 (the total would be multiplied per 109). 
The counts were performed by an experienced histopathologist who was 
blind to the treatment condition. 
Statistical methods: All data are shown as Mean ± S.E.M. One-way 
ANOVA with Tukey’s multiple comparisons test was used when 
appropriate to evaluate the effects of the various treatments. Probability 
levels of less than 0.05 were considered statistically significant. 
For statistical analysis Graph Pad Prism version 4.0 for Windows, Software 
Inc., San Diego, CA, was used.  
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RESULTS 
In the pivotal phase 1 experiments we found that propofol was able to 
induce and sustain “general” anesthesia as per occurrence of loss of the 
righting reflex when an average dose of 200 mg/kg was administered either 
intra-peritoneal (IP) or subcutaneously (SC). The onset time was about 5 to 
10 minutes for the former and 20-25 minutes for the latter. 
The co-administration by both the routes while keeping the IP dose not 
higher than 100 mg/kg, showed the ideal induction time as fast as the IP 
alone, but with less depressive activity on respiration as per the SC 
administration alone. 
As per observation, although not part of the formal assessment, immobility 
to tail pricking was present at doses starting from 200 mg/kg. 
The total duration of the anesthesia for the former doses was about 3-4 
hours and complete recovery can occasionally occur after 5 hours. The 
duration of GA could be extended up to and over 5 hours if a total dosage of 
300 mg was administered, as per 100 mg IP and 200 mg SC, without 
occurring in respiratory depression. 
At 150 mg and 100 mg anesthesia was not achieved either if the 
administration was IP or SC.  
Indeed a deep state of “sedation”, defined as a state of immobility at rest and 
LRR less than 30 seconds (especially with 100 mg/kg) but occasionally 
accompanied by spontaneous movements (more frequent at 100 mg/kg), 
occurred with similar onset times of higher dosages but with duration 
usually less than 2 hours and complete recover in three hours. 
At the histology examination a profound and intense expression of activated 
Caspase3 was found at every site and level where naturally occurring cell 
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death (NOCD) positive profiles presented but with over expression in 
boundaries areas and originally low IHC staining expressing zones. The 
expression was maximal and progressively higher between 150 and 300 mg. 
At 100 mg and 150 mg/kg the pattern of caspase positivity was intense, not 
significantly different and considerably consistent with a sedative/low 
anesthetic dose and a potent pro-apoptotic dose. No hypoglycemic episodes 
were recorded from any of the dosages used as per the random sampling. 
Light microscopy images of activated caspase 3 patterns in control/vehicle 
and propofol treated mouse pups are shown below (Figure 4, 5). 
In phase 2 study we compared groups at different decremented dosages 
starting from 100 mg/kg which was the lowest dose showing a significant 
increase in activated caspase 3 but providing a close anesthetic effect. 
This drug dosage could be compared to the one used in the clinical practice 
for humans in terms of its ability to induce unconsciousness and mild 
analgesia. 
At 100 mg/kg we confirmed the initial loss of righting reflex and of normal 
and regular activity but responsiveness reversed earlier than 2 hours after 
the IP injection. At 50 mg/kg we recorded a sustained resting immobility but 
righting reflex was never lost. At 25 mg/kg a light sedation, pertained of 
reduced regular spontaneous movements, not finalized for a proper 
locomotion but instead an irregular crawling.  
The histological appearance of the pattern of AC3 IHC staining for a 
propofol dose of 200 mg/kg is shown in figure 4. 
The propofol induced AC3 staining cell counts and the dose response curve 
are shown in the set of graphs/figures from 6 to 8. At 50 mg/kg a significant 
increase of activated caspase 3 profiles in the caudate/putamen (P <0.001) 
 63 
and the cortex (P <0.001) was already evident compared to the 
control/vehicle but the apoptosis increased exponentially at 100 mg/kg 
reaching apparently a plateau. 
Lithium treatment induced a reduction of the baseline physiologic occurring 
cell death as per qualitative assessment. 
As co-treatment with propofol, lithium dulled the apoptotic response as per 
qualitatively observation, as shown in the images below (Figure 9). 
Lithium-administered brain sections by cotreatment with propofol were 
morphologically not distinguishable from control/vehicle. 
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Figure 4 
Caspase 3 IHC light microscopy picture of a representative section. Panel A shows a medial (0.40-0.90 mm 
coordinates) section. AC3-positive profiles in the caudate-putamen and cerebral cortex of mouse pup exposed to 
propofol 200 mg/kg. Cortex and Caudate are easily identified. An intense staining at the II-III layer of the cingulate, 
parietal, and V-VI in the occipital and subiculum cortex and a diffuse positivity of the anteroventral caudate, is 
represented. Panel B shows a lateral section (coordinates 2.40-2.90). Panel C shows a particular of the 
caudate/putamen. Panel D shows a particular of the II-III layer of the parietal/occipital cortex. 
 
Panel A 
 
Panel B 
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Figure 5 
AC3-positive profiles IHC light microscopy representative section (coordinates 2.40-2.90) in the caudate-putamen and 
cerebral cortex of mouse pups from vehicle/control (Panel A). In Panel B a detailed image of the parietal cortex.  
 
Control 
 
Cortex Detail 
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Figure 6 
Counts of AC3-positive profiles in the caudate-putamen and cerebral cortex of mouse pups exposed to vehicle/control 
or increasing dosages of propofol at room air after 5 hrs. The mean numbers of AC3-positive profiles is significantly 
increased in all propofol-exposed pups expect for 25 mg/kg (one way ANOVA with Tukey’s post-test correction). 
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Figure 7 
Counts of AC3-positive profiles in the caudate-putamen and cerebral cortex of mouse pups exposed to vehicle/control 
or increasing dosages of propofol at room air after 5 hrs. The means and standard error only are shown.  
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Figure 8 
Counts of AC3-positive profiles vs propofol dose fitting curve in the cerebral cortex. Vehicle/control or increasing 
dosages of propofol at room air after 5 hrs. The means and standard error only are shown.  
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Figure 9 
AC3-positive IHC profiles in the caudate-putamen and cerebral cortex of mouse pups exposed to lithium (6 mEq/kg) 
or propofol (50 mg/kg) or the combo treatment at room air after 5 hrs.  Panel A-B show two control animals. In panel 
B it is possible to notice a higher baseline apoptotic rate as expressed by a-Caspase 3 positive profiles. This is a 
common findings in litters that pretends to have animals in the postnatal day 5. In panel C-D lithium resembles as 
controls. Panel E-F are clearly examples of the potent effect of a single administration of subanesthetic dose of 
propofol in activating caspase 3. The cortex and the caudate/putamen are similarly affected and the pictures takes the 
effects of a “starring sky”. In panel G-H lithium treated animals are like the controls. Lithium depresses or “frozen” the 
activation of caspase 3 preventing new caspase 3 activation. 
Control  
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DISCUSSION AND CONCLUSIONS 
 
Physiological glutamanergic activity is essential to sustain adequate 
synaptic neurotransmission and network activity in the developing brain 
(Agmon and O’Dowd, 1992; Hestrin, 1992). Increasing evidence also 
supports synaptic NMDA receptors in being important for the maturation 
and functionality of synapses (Aamodt and Constantine-Paton, 1999; 
Friedman et al., 2000; Wu et al., 1996). Failure to synchronize presynaptic 
glutamate release and postsynaptic NMDA receptor-induced depolarization 
by different classes of drugs results in defective synaptic neurotransmission 
(Bellinger et al., 2002) and eventually in caspase activated cell death 
(Ishimaru et al., 1999; Dikranian et al., 2001). 
Various clinical disorders in humans (e.g. schizophrenia, learning disorders, 
hyperactivity/attention-deficit) may be the result of interference with normal 
ontogeny of developmental processes in the nervous system requiring 
NMDA receptor activity (Farber and Olney, 2003; Olney et al., 2002). 
Moreover drugs affecting mostly GABAergic agonism and sharing NMDA 
antagonism such as ethanol may result in complex developmental 
syndromes (FAS).  
Olney and collaborators (Olney et al., 2002; Jevtovic-Todorovic et al., 2003; 
Bittigau et al., 1999; Ikonomidou et al., 1999, 2001) showed in different, 
sequential and consistent ways that either activation of GABA R or NMDA 
R inhibition caused significant increase in apoptotic figures in the neonatal 
brain of rats and mice, and they showed in primates as well (recently the 
findings were confirmed by the FDA toxicology research group, Wang et 
al., 2007). 
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The pattern and morphological impact of the cell death in the neonatal rat 
and mouse brain has been well characterized (Ishimaru et al., 1999; 
Dikranian et al., 2001; Ikonomidou et al., 2001, Yon et al., 2005) and the 
implication in terms of functional anatomy, cell migration and brain spurt 
connectivity are consistent with the findings of trophic dependant or action-
potential dependant cell induced apoptosis. 
According to different apoptosis “time schedules”, the areas involved, the 
number of neurons affected and the histology technique utilized (Caspase 3, 
TUNEL, fluorescence, De Olmos cupric silver staining), showed different 
sensitivity, positivization and cell death patterns as per electronic 
microscopy (EM) confirmation. 
For instance PCP and ketamine affect neurons in laterodorsal and ventral 
nuclei of the thalamus laterodorsal anterodorsal anteroventral whereas the 
ethanol pattern also involves ventromedial and mediodorsal thalamic nuclei 
as anteromedial mediodorsal paraventricular central lateral and others, when 
investigated in rats at least 18 hours from the drugs exposure and with De 
Olmos cupric silver staining (Ikonomidou et al., 2001, Dikranian et al., 
2001, Ishimaru et al., 1999). 
Yon et al. looked at the effects of a previous identified general common 
anesthetic drugs apoptotic combination in rats (Jevtovic-Todorovic et al., 
2003), nitrous oxide midazolam and isoflurane, at different age setting and 
at different time course depending on the investigational technique and 
purpose (early cell death caspase 3, developing cell death De Olmos cupric 
silver staining, caspase 8 or 9 for intrinsic or extrinsic apoptosis pathway, 
cytochrome c bcl-xl or Fas for western blotting) and they found an age 
dependent apoptosis peak (7 days post natal), a drug combination induced 
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apoptosis with specific patterns of cell staining and a different involvement 
between intrinsic and extrinsic apoptotic pathway. 
The ethanol pattern of cell death activation and progression of the apoptotic 
damage, as it would be expected by a drug acting on combined blockage of 
NMDA receptors plus activation of GABAA receptors, includes all the 
thalamic nuclei but also spreads over the cerebral cortex and affects early 
and intensively the caudate (Ishimaru et al., 1999; Dikranian et al., 2001, 
Olney et al., 2002). 
In our model we chose a short period of observation since the drug 
administration. Then the most appropriate regions of interest in terms of 
immunostaining with caspase 3 (confirmed reliable by electronic 
microscopy findings, Ishimaru et al., 1999; Dikranian et al., 2001) and in the 
reason of possible neurofunctional implications, were sorted out to be the 
caudate and cortex. Indeed the drug induced apoptosis in the thalamus can 
fully “maturate” and evolve in a moderate late phenomenon (usually 8-18 
hours), while cortex and caudate have an earlier peak of induced cell injury 
(2-8 hours). 
Despite many histology staining methodology (Fluoro Jade and DAPI, 
silver staining, TUNEL), which described fairly the occurrence of cell death 
(Schmued et al., 2000; Natale et al., 2006; Grant et al., 2004; Dikranian et 
al., 2001), caspase 3 is the only one in neonatal age having shown a “bona 
fide” conservation of apoptosis during the early phases of toxicity, as 
confirmed by EM. 
Propofol induced a consistent and quick increase in cleaved caspase 3 
profiles both in the cortex and caudate/putamen. Interestingly the activation 
is very pronounced even at small doses, while the pattern of activation in 
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terms of cortical layer involved, quality of activation and cell types 
activation in cortex and caudate seems genuine of a GABA agonist and 
NMDA antagonist. 
Besides previous reports confirming the areas we chose to study as the 
earliest markers of damage (Young et al., 2005; Yon et al., 2005; 
Ikonomidou et al., 1999 and 2000), and despite the morphological 
characterization of the drug-induced apoptosis in thalamic nuclei, where 
different agents either GABA antagonists (midazolam, diazepam) or NMDA 
agonists (ketamine, nitrous oxide), or by combination (isoflurane, ethanol), 
induced a fairly distinguishable cell staining, in the amount and quality of 
profiles involved, caudate and cortex showed potentiality of morphological 
characterization as well.  
In particular caudate is diffusely stained but with different grades and in 
cortex dendro-dendrites neurons of layers II and III and pyramidal neurons 
in layer V and VI are involved in different ratio and amounts. 
Indeed the patterns of activated caspase 3 showed in different ways while 
using different drugs. In previous experience it was estimated the effect of 
ethanol (Young et al. 2005), ketamine and midazolam (Young et al., 2005), 
and recently we re-assessed the effect of midazolam and ketamine, 
isoflurane and xenon (data not published).  
Ethanol and isoflurane seemed to induced easily a neat and diffuse response 
in caudate and cortex, and in the latter, while involving the cingulate, 
posterior and retrosplenial, they markedly spread profiles from layer II 
down to layer V and VI, then affecting tiny spiny neurons and large 
pyramidal. 
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Besides the single administration of ketamine and midazolam may scatter 
affect the areas under examination and produce a not complete scenario as 
the one depicted above, unless the drugs are used at very high dosages, the 
combination of minimally apoptogenic dosages of midazolam and ketamine 
was able to reproduce the same activation as isoflurane and ethanol. 
On that respect, we found that propofol is able to reproduce the same 
profiles activation especially for doses above 200 mg/kg but as low as 50 
mg/kg. 
Hansen et al., 2004, provided additional evidence for the relevance of pro-
survival NMDA receptor function in the developing brain in vivo. Thus, at 
the time point of extensive synaptogenesis and brain volume growth, 
neonatal rats subjected to pharmacological NMDA receptor blockade 
display severe disseminating apoptotic neurodegeneration (Dikranian et al., 
2001; Ikonomidou et al., 1999; Ishimaru et al., 1999), suggesting that acute 
inhibition of NMDA receptor activity during synaptogenesis triggers 
erroneous neuronal deletion in the developing brain. 
But GABA plays a mutual activity in neuron cell trophism and survival, 
differently affecting the cell function during prenatal and postnatal age, and 
during synaptogenesis and later in brain further development (Ben-Ari et, 
1997; Tyzio et al, 2006; Obrietan et al, 2002) 
Hansen et al., 2004, indicated that depletion of neurotrophin associated 
signaling is an essential mechanism underlying MK801-induced apoptotic 
neurodegeneration in the developing rat brain. Accordingly, MK801 
exposure induced a transcriptional down-regulation of mRNAs encoding the 
synthesis of BDNF, GDNF, and to a lesser degree NT-3. The loss of 
neurotrophin mRNA was a rapidly progressing process and depression of 
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BDNF and GDNF gene expression persisted during neonatal NMDA 
receptor blockade.  
Interestingly, a consequence of repetitive MK801 administration was the 
reduction of ERK 1/2 catalytic activity, down-regulation of CREB 
phosphorylation and a transcriptional reduction of the antiapoptotic protein 
Bcl2. These regulatory events occurred temporally in parallel to the drop in 
neurotrophin expression, signifying a causal relationship. 
Growing up evidences with ethanol showed the mutual relantionship of 
gabaergic and glutamanergic interactions and stimulation/inhibition effects. 
As Young et al, 2006, demonstrated, ethanol reduces the phosphorylation of 
Erk and Akt. 
The finding that developmental receptor inhibition leads to reduced activity 
of the ERK 1/2-CREB signaling pathway is in accordance with mounting 
evidence that CREB functionality is essential for neuronal survival during 
brain development. Correspondingly, CREB gene null mutations result in 
extensive neuronal apoptosis and perinatal death of homozygous mice 
(Lonze et al., 2002), and conditional CREB knockout mice display 
progressing apoptotic neurodegeneration during postnatal forebrain 
development (Mantamadiotis et al., 2002). It is recognized that NMDA 
receptor-induced membrane depolarization can stimulate neuronal gene 
expression by triggering calcium-dependent signaling transduction via 
phosphorylation of ERK 1/2 (Hardingham and Bading, 2003; Kornhauser et 
al., 2003) and CaMKIV (Impey et al., 2002; Wu et al., 2001). 
Activation of these pathways leads to enhanced activity of CREB mediated 
gene transcription (Hardingham and Bading 2003; Wu et al., 2001). Since 
CREB regulates transcription of many pro-survival genes, including bdnf 
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(Hardingham et al., 2002; West et al., 2001) and bcl2 (Bonni et al., 1999), 
the association of NMDA receptors to ERK1/2-CREB and CaMKIV-CREB 
signaling is suggested to be important for NMDA receptor-induced trophic 
effects during brain development (Finkbeiner, 2000; Hardingham and 
Bading, 2002). 
Recently reported that erythropoietin supplementation partly rescues 
newborn rats from MK801-induced brain damage by enhancing BDNF and 
GDNF production and restoring ERK1/2 signaling (Dzietko et al., 2004), 
signifying that the observed partial deactivation of the ERK1/2-CREB 
signaling is causally linked to the pathogenesis of MK801-induced cell 
death and is not simply an accompanying phenomenon. 
Propofol has a unique affection of the intracellular mechanisms related to 
the messenger transmission through the NMDA receptor, bridging the dual 
effects on the GABAa receptor and the NMDA receptor (Kozinn et al, 
2007), and this dual mechanism may contribute to its peculiar 
pharmacological effects and to its pro-apoptogenic properties during the 
neurodevelopment as well. 
Lithium is able to promote survival of cells and abolish the apoptosis. This 
is practically demonstrated by post treatment termination of newly induced 
activation of caspase 3 and confirmed by a reduction of the base line 
immunostaining (cells already apoptotic) for early stages or through a 
complete absence of signal at later stages. As well every drug induced 
apoptosis is blunted to a stage that resembles a NOCD native stage and 
consequentially the cell protection preservation, at later stages observation 
the immunostaining is blank. 
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The last issue that needs to be mentioned is the alteration and 
activation/deactivation of ion channel receptors in terms of synaptic and 
extrasynaptic activity and their structural modification in terms of subunit 
composition during the neurodevelopment. 
It is known that the GABAA receptor modified the relative composition 
between its subunits during the synaptic spurt (Fritschy et al., 1994), and 
NMDA receptor as well modified its subunits composition on regard of 
NR2 A and B (Hardingham, 2006), but the relevance of these findings on 
the cell survival and drug-induced apoptosis needs further evaluation and 
are beyond the scope of this dissertation. 
In conclusion, despite frank neurodevelopmental diseases and 
neurobehavioural syndromes are associated to structural brain anomalies 
(FAS, schizophrenia, etc), subtle drug-induced abnormalities during the 
brain development affecting structure and function of the neuronal cells 
cannot be ruled out easily, and they may still occur even at low doses while 
we are missing the general effects. 
Hence, the novel experimental evidence we present calls for caution with 
the use of propofol in neonatal and pediatric medicine.  
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Future developments 
Understanding the mechanisms underlying developmental molecular 
biology of NMDA receptor antagonism and GABAergic agonism 
neurotoxicity and the protective mechanisms involved in lithium induced 
genes expression and caspase 3 inhibition, may offer adjunctive 
neuroprotective measures which will counteract the cell toxicity in cases 
where administration of NMDA receptor blockers or GABA mimetic drugs 
cannot be substituted. 
Ethanol and MK-801 have been shown to produce consistent modification 
of genes involved in apoptosis and survival and consequentially the 
products of those genes. Propofol has been shown in vitro to affect Erk 1/2. 
Preliminary data seems to confirm the findings in vivo but further 
evaluations are necessary. 
We then aim to study in vivo the potential role of propofol to affect 
expression of proteins Erk 1/2 and Akt involved in the apoptosis/survival 
pathways. Moreover we aim to assess the morphologic pattern of cell death 
at different time points and in different brain region (thalamus, cerebellum). 
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